• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • EMBELIN
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • AMPK
      • ANTI AGING
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CARDIAC GLYCOSIDES
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • ELLAGITANNINS
      • EPIGENETIC MODIFIERS
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • FASTING & CANCER
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GALLOTANNINS
      • GLUTAMATE & BRAIN
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HSP90 INHIBITORS
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LIFESPAN EXTENSION
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MITOCHONDRIAL UNCOUPLING
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROINFLAMMATION
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SIRT1 & LONGEVITY
      • SUGAR & AGING
      • STAT3
      • TELOMERE SHORTENING & PREMATURE AGING
      • TRAUMATIC BRAIN INJURY (HEALING)
    • HOME
    • FAQ
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    JNK PREVENTS PREMATURE SENESCENCE
    January 10, 2020
    SENESCENT CELLS, SASP & SENOLYTICS
    January 14, 2020

    MDM2 antagonists attenuate the senescence-associated secretory phenotype

    Processes that have been linked to aging and cancer include an inflammatory milieu driven by senescent cells. Senescent cells lose the ability to divide, essentially irreversibly, and secrete numerous proteases, cytokines and growth factors, termed the senescence-associated secretory phenotype (SASP). Senescent cells that lack p53 tumor suppressor function show an exaggerated SASP, suggesting the SASP is negatively controlled by p53. Here, we show that increased p53 activity caused by small molecule inhibitors of MDM2, which promotes p53 degradation, reduces inflammatory cytokine production by senescent cells. Upon treatment with the MDM2 inhibitors nutlin-3a or MI-63, human cells acquired a senescence-like growth arrest, but the arrest was reversible. Importantly, the inhibitors reduced expression of the signature SASP factors IL-6 and IL-1α by cells made senescent by genotoxic stimuli, and suppressed the ability of senescent fibroblasts to stimulate breast cancer cell aggressiveness. Our findings suggest that MDM2 inhibitors could reduce cancer progression in part by reducing the pro-inflammatory environment created by senescent cells.

    SCIENTIFIC STUDIES

    1. A Computational Analysis Of Binding Modes And Conformation Changes Of MDM2 Induced By P53 And Inhibitor Bindings
    2. A Dimethylbromobenzene-Cysteine Stapled Peptide Dual Inhibitor Of The P53-MDM2/Mdmx Interactions
    3. A Gene Signature Composed Of 13 P53 Target Genes Predicts For Response To Nvp-Cgm097, A Novel P53-MDM2 Inhibitor, In Cell Lines And In Human Primary Tumor …
    4. A Novel Orally Active MDM2 Inhibitor (Mi-219) Activates The P53 Pathway And Is Selectively Toxic To Tumor Cells
    5. A novel small molecular inhibitor targets the MDM2-p53 interaction significantly reducing cell viability in both embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
    6. A Novel Small Molecule Inhibitor Of MDM2-P53 (Apg-115) Enhances Radiosensitivity Of Gastric Adenocarcinoma
    7. A Novel Small Molecule Inhibitor Of MDM2-P53 (Apg-115) Has Antitumor Activity In Gastric Adenocarcinoma
    8. A Potent Small-Molecule Inhibitor Of The MDM2–P53 Interaction (Mi-888) Achieved Complete And Durable Tumor Regression In Mice
    9. Abstract 2658: 18F-FLT PET imaging for noninvasive, early assessment of tumor response to MDM2-p53 disruption using a novel MDM2 inhibitor
    10. Abstract 5505: Synergistic anticancer activity of clinical stage, non-genotoxic apoptosis inducing agents RG7388 (MDM2 antagonist) and ABT-199 (GDC-0199, BCL2 inhibitor) in p53 wild-type AML tumor models
    11. Abstract B35: Reactivation Of P53 Signaling In Hepatoblastoma With A Stapled Peptide Dual Inhibitor Of MDM2 And Mdm4
    12. Abstract P1-03-02: Preclinical Efficacy Of A Novel And Potent Inhibitor Of The MDM2-P53 Axis Amg 232 In Er+ Breast Cancer Model
    13. Abstract P3-07-21: Cytotoxic Potential Of The Rg7388 MDM2-P53 Binding Antagonist And The Gsk2830371 Wip1 Inhibitor On Mx-1 And Mcf-7 Human Breast Cancer …
    14. Activation Of P53 By The MDM2 Inhibitor Rg7112 Impairs Thrombopoiesis
    15. Activation of p53 in the tumor microenvironment by MDM2 inhibitor APG-115 synergizes with PD-1 blockade independently of p53 status of tumor cells
    16. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
    17. Adaptation Of Cancer Cells From Different Entities To The MDM2 Inhibitor Nutlin-3 Results In The Emergence Of P53-Mutated Multi-Drug-Resistant Cancer Cells
    18. Amelioration Of Radiation Esophagitis By Orally Administered P53/MDM2/Mdm4 Inhibitor (Beb55) Or Gs-Nitroxide
    19. Amg 232, A Small Molecular Inhibitor Of MDM2 Augments Radiation Response In Human Tumors Harboring Wild-Type P53
    20. An Expeditious Synthesis Of The MDM2–P53 Inhibitor Am-8553
    21. Anticancer Effects Of A New Sirt Inhibitor, Mhy2256, Against Human Breast Cancer Mcf-7 Cells Via Regulation Of MDM2-P53 Binding
    22. Atm-Mediated Phosphorylations Inhibit Mdmx/MDM2 Stabilization By Hausp In Favor Of P53 Activation
    23. Binding Of An Inhibitor Of The P53/MDM2 Interaction To MDM2
    24. Catalytic, Enantioselective Synthesis Of Stilbene Cis-Diamines: A Concise Preparation Of (−)-Nutlin-3, A Potent P53/MDM2 Inhibitor
    25. Cellular Pharmacokinetic And Activity Studies With The MDM2-P53 Inhibitor Nutlin-3
    26. Co-Delivery Of P53 And MDM2 Inhibitor Rg7388 Using A Hydroxyl Terminal Pamam Dendrimer Derivative For Synergistic Cancer Therapy
    27. Comparison Of The Antitumor Effects Of An MDM2 Inhibitor, Nutlin-3, In Feline Lymphoma Cell Lines With Or Without P53 Mutation
    28. Conditional Allele Of MDM2 Which Encodes A P53 Inhibitor
    29. Control Of The P53 Protein-MDM2 Inhibitor System Using Nonlinear Kalman Filtering.
    30. Development Of Cell‐Penetrating Peptide‐Based Drug Leads To Inhibit Mdmx: P53 And MDM2: P53 Interactions
    31. Development Of Noncytotoxic Plga Nanoparticles To Improve The Effect Of A New Inhibitor Of P53–MDM2 Interaction
    32. Discovery Of A Nanomolar Inhibitor Of The Human Murine Double Minute 2 (MDM2)− P53 Interaction Through An Integrated, Virtual Database Screening Strategy
    33. Discovery Of A New Inhibitor Of P53/MDM2 Interaction Using A Yeast Target-Based Screening Strategy
    34. Discovery Of A New Small-Molecule Inhibitor Of P53–MDM2 Interaction Using A Yeast-Based Approach
    35. Discovery Of Am-7209, A Potent And Selective 4-Amidobenzoic Acid Inhibitor Of The MDM2–P53 Interaction
    36. Discovery Of Amg 232, A Potent, Selective, And Orally Bioavailable MDM2–P53 Inhibitor In Clinical Development
    37. Discovery Of Amg 232, An Inhibitor Of The MDM2-P53 Interaction: From Lead To A Clinical Candidate
    38. Discovery Of Ds-5272 As A Promising Candidate: A Potent And Orally Active P53–MDM2 Interaction Inhibitor
    39. Discovery Of Rg7388, A Potent And Selective P53–MDM2 Inhibitor In Clinical Development
    40. Discovery Of Scy45, A Natural Small‐Molecule MDM2‐P53 Interaction Inhibitor
    41. Dose And Schedule Determine Distinct Molecular Mechanisms Underlying The Efficacy Of The P53–MDM2 Inhibitor Hdm201
    42. Double-Edged Swords As Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit P53–MDM2 Interaction And The Nf-Κb Pathway
    43. Downregulation Of MDM2 Leads To Anti-Proliferative Effects Through Activation Of P53-Associated Pathway Mediated By Both Dual Inhibitor Mx69 And Mir-548C-3P In …
    44. Efficient Reactivation Of P53 In Cancer Cells By A Dual Mdmx/MDM2 Inhibitor
    45. Fluorescence Polarization Assay And Inhibitor Design For MDM2/P53 Interaction
    46. Front Cover: Discovery Of Scy45, A Natural Small‐Molecule MDM2‐P53 Interaction Inhibitor (C&B 6/2019)
    47. Functional Consequences Of Retro-Inverso Isomerization Of A Miniature Protein Inhibitor Of The P53–MDM2 Interaction
    48. Histone Deacetylase Inhibitor Sodium Butyrate Suppresses Proliferation And Promotes Apoptosis In Osteosarcoma Cells By Regulation Of The MDM2–P53 …
    49. Hoiamide D, A Marine Cyanobacteria-Derived Inhibitor Of P53/MDM2 Interaction
    50. How To Design A Successful P53–MDM2/X Interaction Inhibitor: A Thorough Overview Based On Crystal Structures
    51. Hsp90 Inhibitor Biib021 Enhances Triptolide-Induced Apoptosis Of Human T-Cell Acute Lymphoblastic Leukemia Cells In Vitro Mainly By Disrupting P53-MDM2 …
    52. Human Glioblastoma Multiforme: P53 Reactivation By A Novel MDM2 Inhibitor
    53. I-58 Sylvie Retout Prediction Of Occurrence Of Thrombocytopenia To Select Phase 1B Dose And Dosing Regimen For A Selective Inhibitor Of P53-MDM2 In Patients With …
    54. Identification Of A New P53/MDM2 Inhibitor Motif Inspired By Studies Of Chlorofusin
    55. Identification Of Antipsychotic Drug Fluspirilene As A Potential P53-MDM2 Inhibitor: A Combined Computational And Experimental Study
    56. In Vitro And In Vivo Characterization Of A Novel, Highly Potent P53-MDM2 Inhibitor
    57. In Vitro Characterization Of A Potent P53-MDM2 Inhibitor, Rg7112 In Neuroblastoma Cancer Cell Lines
    58. Inhibition Of S-Adenosylmethionine Decarboxylase By Inhibitor Sam486A Connects Polyamine Metabolism With P53-MDM2-Akt/Protein Kinase B Regulation And …
    59. In-Tether Chiral Center Induced Helical Peptide Modulators Target P53-MDM2/Mdmx And Inhibit Tumor Growth In Stem-Like Cancer Cell
    60. Investigation Of The In-Vivo Cytotoxicity And The In Silico-Prediction Of MDM2-P53 Inhibitor Potential Of Euphorbia Peplus Methanolic Extract In Rats
    61. Life Science: Hoiamide D, A Marine Cyanobacteria-Derived Inhibitor Of P53/MDM2 Interaction
    62. MDM2 Antagonist Can Inhibit Tumor Growth In Hepatocellular Carcinoma With Different Types Of P53 In Vitro
    63. MDM2 Inhibitor Mi-319 In Combination With Cisplatin Is An Effective Treatment For Pancreatic Cancer Independent Of P53 Function
    64. MDM2 Inhibitor Mi-319 In Combination With Cisplatin/Oxaliplatin Is An Effective Treatment For Pancreatic Cancer Independent Of P53 Function
    65. MDM2 Inhibitor Nutlin-3A Induces Apoptosis And Senescence In Cutaneous T-Cell Lymphoma: Role Of P53
    66. MDM2 Inhibitor Nutlin-3A Induces P53-Dependent Apoptosis Via Transcription-Dependent And-Independent Pathways And Overcomes Fludarabine-Resistance In Cll
    67. MDM2 Inhibitor Rg7388 Potently Inhibits Tumors By Activating P53 Pathway In Nasopharyngeal Carcinoma
    68. MDM2 Inhibitor, Nutlin 3A, Induces P53 Dependent Autophagy In Acute Leukemia By Amp Kinase Activation
    69. MDM2-Nfat1 Dual Inhibitor, Ma242: Effective Against Hepatocellular Carcinoma, Independent Of P53
    70. MDM2-P53 Interaction Inhibitor With Cisplatin Enhances Apoptosis In Colon And Prostate Cancer Cells In-Vitro
    71. Mdm4 And MDM2 Cooperate To Inhibit P53 Activity In Proliferating And Quiescent Cells In Vivo
    72. Mdmx Overexpression Prevents P53 Activation By The MDM2 Inhibitor Nutlin
    73. Mechanistic Study Of Nvp-Cgm097: A Potent, Selective And Species Specific Inhibitor Of P53-MDM2
    74. Methyl Elaidate: A Major Compound Of Potential Anticancer Extract Of Moringa Oleifera Seeds Binds With Bax And MDM2 (P53 Inhibitor) In Silico
    75. Mi-63: A Novel Small-Molecule Inhibitor Targets MDM2 And Induces Apoptosis In Embryonal And Alveolar Rhabdomyosarcoma Cells With Wild-Type P53
    76. Network Modeling Of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy In Wt-P53 Solid Tumors
    77. New Inhibitor Of The Tap73 Interaction With MDM2 And Mutant P53 With Promising Antitumor Activity Against Neuroblastoma
    78. Non-Linear Feedback Control Of The P53 Protein–MDM2 Inhibitor System Using The Derivative-Free Non-Linear Kalman Filter
    79. Novel MDM2 Inhibitor Sar405838 (Mi-773) Induces P53-Mediated Apoptosis In Neuroblastoma
    80. N-Terminal 130 Amino Acids Of MDM2 Are Sufficient To Inhibit P53-Mediated Transcriptional Activation.
    81. Nutlin-3, The Small-Molecule Inhibitor Of MDM2, Promotes Senescence And Radiosensitises Laryngeal Carcinoma Cells Harbouring Wild-Type P53
    82. Nvp-Cgm097: A Novel P53-MDM2 Inhibitor Exhibiting Potent Antitumor Activity In Mouse Models Of Human Cancer
    83. Nvp-Hdm201: Biochemical And Biophysical Profile Of A Novel Highly Potent And Selective Ppi Inhibitor Of P53-MDM2
    84. Nvp-Hdm201: Cellular And In Vivo Profile Of A Novel Highly Potent And Selective Ppi Inhibitor Of P53-MDM2
    85. On The Biosynthesis Of An Inhibitor Of The P53/MDM2 Interaction
    86. Organocatalytic Diastereoselective [3+ 2] Cyclization Of Mbh Carbonates With Dinucleophiles: Synthesis Of Bicyclic Imidazoline Derivatives That Inhibit MDM2–P53 …
    87. P53 Expression Controls Prostate Cancer Sensitivity To Chemotherapy And The MDM2 Inhibitor Nutlin-3
    88. P53 Mediated Death Of Cells Overexpressing MDM2 By An Inhibitor Of MDM2 Interaction With P53
    89. P709 A Novel MDM2 Inhibitor, Sm13, Induces P53-Dependent Apoptosis In Vascular Smooth Muscle Cell.
    90. Pd-1/Pd-L1 Blockade Enhances MDM2 Inhibitor Activity In P53 Wild-Type Cancers
    91. Pharmacokinetics And Metabolism Of Amg 232, A Novel Orally Bioavailable Inhibitor Of The MDM2–P53 Interaction, In Rats, Dogs And Monkeys: In Vitro–In Vivo …
    92. Phase 1 Study Of The MDM2 Inhibitor Amg 232 In Patients With Advanced P53 Wild-Type Solid Tumors Or Multiple Myeloma
    93. Phase 1 Study Of The P53-MDM2 Inhibitor Amg 232 Combined With Trametinib Plus Dabrafenib Or Trametinib In Patients (Pts) With Tp53 Wild Type (Tp53Wt) Metastatic …
    94. Preclinical Characterization Of Mi-219, A Novel, Potent And Orally Active Small Molecule Inhibitor Of The MDM2-P53 Interaction.
    95. Protoporphyrin Ix Is A Dual Inhibitor Of P53/MDM2 And P53/Mdm4 Interactions And Induces Apoptosis In B-Cell Chronic Lymphocytic Leukemia Cells
    96. Radiosensitization Of Wildtype P53 Cancer Cells By The MDM2-Inhibitor Pxn727 Is Associated With Altered Heat Shock Protein 70 (Hsp70) Levels
    97. Reactivation Of P53 By MDM2 Inhibitor Mi-77301 For The Treatment Of Endocrine-Resistant Breast Cancer
    98. Reactivation Of The P53 Pathway By MDM2 Inhibitor Nutlin-3: Application In Photochemical Internalisation (Pci)
    99. Recombinant Dual-Target MDM2/Mdmx Inhibitor Reverses Doxorubicin Resistance Through Activation Of The Tab1/Tak1/P38 Mapk Pathway In Wild-Type P53 …
    100. Retraction Of “Efficient Reactivation Of P53 In Cancer Cells By A Dual Mdmx/MDM2 Inhibitor”
    101. Sar405838: A Novel And Potent Inhibitor Of The MDM2: P53 Axis For The Treatment Of Dedifferentiated Liposarcoma
    102. Sar405838: An Optimized Inhibitor Of MDM2–P53 Interaction That Induces Complete And Durable Tumor Regression
    103. Sf1126, A Novel Pan-Pi3K Inhibitor, Inhibits Activation Of MDM2 And Increases Sensitivity To Doxorubicin In Wild Type P53 Neuroblastoma Cell Lines
    104. Small Molecule Inhibitor Of MDM2 Induces P53-Dependent Hmgb1 Secretion Followed By Apoptosis In Cancer Cells And Incomplete Senescence In Normal Fibroblasts
    105. Solid-Phase Synthesis Of The Cyclic Peptide Portion Of Chlorofusin, An Inhibitor Of P53-MDM2 Interactions
    106. Stapled Α− Helical Peptide Drug Development: A Potent Dual Inhibitor Of MDM2 And Mdmx For P53-Dependent Cancer Therapy
    107. Structural Studies On A P53-MDM2 Inhibitor
    108. Superior Anti-Tumor Activity Of The MDM2 Antagonist Idasanutlin And The Bcl-2 Inhibitor Venetoclax In P53 Wild-Type Acute Myeloid Leukemia Models
    109. Surface Plasmon Resonance And Cytotoxicity Assays Of Drug Efficacies Predicted Computationally To Inhibit P53/MDM2 Interaction
    110. Synergistic Effect Of Combination Treatment With Mi-219, A Small Molecule Inhibitor Of The MDM2-P53 Interaction, And Kinase Inhibitors Or Chemotherapeutic Agents.
    111. Targeting P53-MDM2 Interaction Using A Potent MDM2 Inhibitor To Overcome Cisplatin Resistance In Head And Neck Squamous Cell Carcinoma
    112. Targeting The P53 Tumor Suppressor Activity In Glioblastomas Using Small Molecule MDM2-Inhibitor
    113. Temporal Activation Of P53 By A Specific MDM2 Inhibitor Is Selectively Toxic To Tumors And Leads To Complete Tumor Growth Inhibition
    114. The Cellular P53 Inhibitor MDM2 And The Growth Factor Receptor Flt3 As Biomarkers For Treatment Responses To The MDM2-Inhibitor Idasanutlin And The Mek1 Inhibitor …
    115. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by MDM2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
    116. The Hdm2 (MDM2) Inhibitor Nvp-Cgm097 Inhibits Tumor Cell Proliferation And Shows Additive Effects With 5-Fluorouracil On The P53-P21-Rb-E2F1 Cascade In The …
    117. The Human Oncoprotein MDM2 Uses Distinct Strategies To Inhibit Transcriptional Activation Mediated By The Wild-Type P53 And Its Tumor-Derived Mutants
    118. The Hydrophobically-Tagged MDM2–P53 Interaction Inhibitor Nutlin-3A-Ht Is More Potent Against Tumor Cells Than Nutlin-3A
    119. The Isolation, Total Synthesis And Structure Elucidation Of Chlorofusin, A Natural Product Inhibitor Of The P53–MDM2 Protein–Protein Interaction
    120. The MDM2 Inhibitor Amg 232 Demonstrates Robust Antitumor Efficacy And Potentiates The Activity Of P53-Inducing Cytotoxic Agents
    121. The MDM2 Inhibitor, Nutlin–3A, Is Capable Of Inhibiting Endothelial Cell Proliferation Via P53 Mediated Apoptosis
    122. The MDM2 Small-Molecule Inhibitor Rg7388 Leads To Potent Tumor Inhibition In P53 Wild-Type Neuroblastoma
    123. The MDM2-Inhibitor Nutlin-3 Synergizes With Cisplatin To Induce P53 Dependent Tumor Cell Apoptosis In Non-Small Cell Lung Cancer
    124. The Nedd8 Inhibitor Mln4924 Increases The Size Of The Nucleolus And Activates P53 Through The Ribosomal-MDM2 Pathway
    125. The P53 Inhibitor MDM2 Facilitates Sonic Hedgehog-Mediated Tumorigenesis And Influences Cerebellar Foliation
    126. The P53 Tumor Suppressor Protein Does Not Regulate Expression Of Its Own Inhibitor, MDM2, Except Under Conditions Of Stress
    127. The P53-MDM2 Interaction: Predicting Helix Mimetic Side-Chain Modifications Likely To Increase Inhibitor Affinity
    128. The Pre-Clinical Development Of MDM2 Inhibitors In Chronic Lymphocytic Leukemia Uncovers A Central Role For P53 Status In Sensitivity To MDM2 Inhibitor-Mediated …
    129. The Role Of P53 And P21 In Cancer Therapy With MDM2 Inhibitor.
    130. Use Of A Retroinverso P53 Peptide As An Inhibitor Of MDM2
    Share
    0
    Interstellar Blend
    Interstellar Blend

    Related posts

    April 14, 2021

    NEUROPROTECTIVE AGENTS


    Read more
    April 14, 2021

    CARDIOPROTECTIVE AGENTS


    Read more
    April 14, 2021

    ADAPTOGENS


    Read more

    Comments are closed.

    Recent Posts

    • NEUROPROTECTIVE AGENTS
    • CARDIOPROTECTIVE AGENTS
    • ADAPTOGENS
    • MUSCLE ATROPHY (PREVENTING)
    • MYOGENESIS
    © 2021 Interstellar Blends | Activate Your Super Powers!. © 2019 Interstellar Blends | Activate Your Super Powers!. All Rights Reserved.

    Mandatory FDA Disclaimer
    Privacy Policy
    Terms and Conditions
    Have Questions?
    Contact Gavin Robert McGowen Here

    Join the following facebook groups to learn more:
    Ultimate Weightloss Challenge , Dry Fasting, Longevity Agents , Interstellar Blend Seven Sages, The Infinitely Postive, THE INTERSTELLAR BLEND CHALLENGE: Fluid Restricted Fasting w/ Superherbs

    Love this Website? Contact David Rodriguez to build you one!